Allogene Therapeutics (ALLO) stock forecast for 2026
Last update: 08-15-2022, 12:50
Sector: HealthcareThe share price of Allogene Therapeutics, Inc. (ALLO) now
What analysts predict:: $27.44
52-week high/low: $27.86 / $6.43
50/200 Day Moving Average: $12.19 / $12.03
This figure corresponds to the average price over the previous 50/200 days. For Allogene Therapeutics stocks, the 50-day moving average is the support level today.
For Allogene Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Allogene Therapeutics stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Allogene Therapeutics stock price in 2026. How much will one Allogene Therapeutics share be worth in 2026?
Is it worth taking profit / loss on Allogene Therapeutics stock now or waiting? What are analysts' forecasts for Allogene Therapeutics stock?
We forecast Allogene Therapeutics stock performance using neural networks based on historical data on Allogene Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Allogene Therapeutics stock prediction results are shown below and presented as a graph, table and text information.
Allogene Therapeutics stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Allogene Therapeutics analysts is $27.44.
Today 200 Day Moving Average is the support level (12.03 $).
50 Day Moving Average is the support level (12.19 $).
Historical and forecast chart of Allogene Therapeutics stock
The chart below shows the historical price of Allogene Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Allogene Therapeutics stock price can be found in the table below.
Allogene Therapeutics (ALLO) Forecast for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 19.85 | 18.60 | 20.63 | 9.82 % |
| Feb | 19.79 | 19.28 | 21.28 | 9.40 % |
| Mar | 19.79 | 18.21 | 20.43 | 10.85 % |
| Apr | 20.90 | 20.46 | 22.07 | 7.29 % |
| May | 22.14 | 21.10 | 22.89 | 7.83 % |
| Jun | 24.04 | 23.05 | 25.48 | 9.53 % |
| Jul | 22.91 | 21.54 | 24.35 | 11.57 % |
| Aug | 22.11 | 20.56 | 23.46 | 12.35 % |
| Sep | 23.59 | 22.34 | 25.08 | 10.91 % |
| Oct | 24.44 | 22.83 | 26.39 | 13.52 % |
| Nov | 25.91 | 24.43 | 27.98 | 12.69 % |
| Dec | 24.82 | 22.86 | 25.79 | 11.36 % |
Allogene Therapeutics information and performance
Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in the State of California.
Allogene Therapeutics Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, US
Market Capitalization: 2 480 671 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -294 208 992 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -2.2
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.955
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 7893.34
Enterprise Value (EV) /Revenue
EV To EBITDA: -6.63
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 143807000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Allogene Therapeutics price target for 2021 by month
Target values for the price of one Allogene Therapeutics share for Jan 2026.
Pessimistic target level: 18.60
Optimistic target level: 20.63
Target values for the price of one Allogene Therapeutics share for Feb 2026.
Pessimistic target level: 19.28
Optimistic target level: 21.28
Target values for the price of one Allogene Therapeutics share for Mar 2026.
Pessimistic target level: 18.21
Optimistic target level: 20.43
Target values for the price of one Allogene Therapeutics share for Apr 2026.
Pessimistic target level: 20.46
Optimistic target level: 22.07
Target values for the price of one Allogene Therapeutics share for May 2026.
Pessimistic target level: 21.10
Optimistic target level: 22.89
Target values for the price of one Allogene Therapeutics share for Jun 2026.
Pessimistic target level: 23.05
Optimistic target level: 25.48
Target values for the price of one Allogene Therapeutics share for Jul 2026.
Pessimistic target level: 21.54
Optimistic target level: 24.35
Target values for the price of one Allogene Therapeutics share for Aug 2026.
Pessimistic target level: 20.56
Optimistic target level: 23.46
Target values for the price of one Allogene Therapeutics share for Sep 2026.
Pessimistic target level: 22.34
Optimistic target level: 25.08
Target values for the price of one Allogene Therapeutics share for Oct 2026.
Pessimistic target level: 22.83
Optimistic target level: 26.39
Target values for the price of one Allogene Therapeutics share for Nov 2026.
Pessimistic target level: 24.43
Optimistic target level: 27.98
Target values for the price of one Allogene Therapeutics share for Dec 2026.
Pessimistic target level: 22.86
Optimistic target level: 25.79
